Ovid Therapeutics Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
Ovid Therapeutics Inc. (OVID) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $324.31 thousand for the 9-month period ending 2021-09-30, per its 10-Q filed 2021-11-10.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2021-11-10
- Ovid Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2021-09-30 was $261.89K, a 86.65% increase year-over-year.
- Ovid Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2021-06-30 was $55.58K.
- Ovid Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2021-03-31 was $6.84K.
- Ovid Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2020-09-30 was $140.31K.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month |
|---|---|---|---|
| 2021-09-30 | $261.89K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $317.48K derived: sum of 2 quarters · filed 2021-11-10 | $324.31K 10-Q · filed 2021-11-10 |
| 2021-06-30 | $55.58K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | $62.42K 10-Q · filed 2021-08-16 | |
| 2021-03-31 | $6.84K 10-Q · filed 2021-05-13 | ||
| 2020-09-30 | $140.31K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-13 | $488.38K 10-Q · filed 2020-11-13 | |
| 2020-06-30 | $348.07K 10-Q · filed 2020-08-10 | ||
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $31.13K 10-Q · filed 2018-11-08 | |
| 2018-06-30 | $31.13K 10-Q · filed 2018-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |